Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HNS001
MIFTS: 36

Hansen's Disease

Categories: Neuronal diseases, Rare diseases, Skin diseases
Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Hansen's Disease

About this section

MalaCards integrated aliases for Hansen's Disease:

Name: Hansen's Disease 54 3
Leprosy 54 74

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Neuronal diseases Skin diseases
See all MalaCards categories (disease lists)


External Ids:

UMLS 74 C0023343
Sources

Summaries for Hansen's Disease

About this section
NIH Rare Diseases : 54 Hansen's disease (also known as leprosy) is a rare bacterial infection that affects the skin, nerves and mucous membranes. After exposure, it may take anywhere from 2 to 10 years to develop features of the condition. Once present, common signs and symptoms include skin lesions; muscle weakness or paralysis; eye problems that may lead to blindness; nosebleeds; severe pain; and/or numbness in the hands, feet, arms and legs. Hansen's disease is caused by the bacterium Mycobacterium leprae; however, the way in which the bacterium is transmitted (spread) is poorly understood. It appears that only about 5% of people are susceptible to the condition. Hansen's disease is easily treated with combination antibiotics for 6 months to 2 years.

MalaCards based summary : Hansen's Disease, also known as leprosy, is related to leprosy 1 and indeterminate leprosy. An important gene associated with Hansen's Disease is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2). The drugs Clofazimine and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and eye.

Wikipedia : 77 Leprosy, also known as Hansen''s disease (HD), is a long-term infection by the bacteria Mycobacterium... more...

Sources

Related Diseases for Hansen's Disease

About this section

Diseases related to Hansen's Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 392)
# Related Disease Score Top Affiliating Genes
1 leprosy 1 12.6
2 indeterminate leprosy 12.6
3 leprosy 5 12.3
4 leprosy 2 12.3
5 leprosy 4 12.3
6 leprosy 6 12.2
7 leprosy 3 11.5
8 trigeminal trophic syndrome 11.4
9 buruli ulcer 11.4
10 chronic rhinitis 11.3
11 fetal thalidomide syndrome 11.3
12 macs syndrome 11.0
13 mycobacterium kansasii 11.0
14 neuropathy 10.3
15 lagophthalmos 10.3
16 hepatitis 10.3
17 australia antigen 10.2
18 hepatitis b 10.1
19 psoriasis 10.1
20 malaria 10.1
21 tetanus 10.0
22 onchocerciasis 10.0
23 pulmonary tuberculosis 10.0
24 molluscum contagiosum 10.0
25 systemic lupus erythematosus 10.0
26 pelger-huet anomaly 10.0
27 sarcoidosis 1 10.0
28 hepatitis c 10.0
29 human immunodeficiency virus infectious disease 10.0
30 carpal tunnel syndrome 10.0
31 mononeuropathy of the median nerve, mild 10.0
32 lymphoma 10.0
33 tuberculoid leprosy 10.0
34 filariasis 10.0
35 yemenite deaf-blind hypopigmentation syndrome 10.0
36 elephantiasis 10.0
37 dysautonomia 10.0
38 mycosis fungoides 9.9
39 yaws 9.9
40 facial paralysis 9.9
41 antiphospholipid syndrome 9.9
42 scabies 9.9
43 mucocutaneous leishmaniasis 9.9
44 iridocyclitis 9.9
45 granulocytopenia 9.9
46 mycobacterium tuberculosis 1 9.9
47 hepatitis c virus 9.9
48 cataract 9.9
49 crohn's disease 9.9
50 granuloma annulare 9.9

Graphical network of the top 20 diseases related to Hansen's Disease:



Diseases related to Hansen's Disease
Sources

Symptoms & Phenotypes for Hansen's Disease

About this section
Sources

Drugs & Therapeutics for Hansen's Disease

About this section

Drugs for Hansen's Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 148)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clofazimine Approved, Investigational Phase 4,Phase 1,Phase 2 2030-63-9 2794
2
leucovorin Approved Phase 4,Phase 1,Phase 2,Not Applicable 58-05-9 6006 143
3
Rifampicin Approved Phase 4,Phase 2,Phase 3,Phase 1 13292-46-1 5381226 5458213
4
Dapsone Approved, Investigational Phase 4,Phase 1,Phase 2 80-08-0 2955
5
Isoniazid Approved, Investigational Phase 4,Phase 1 54-85-3 3767
6
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 59-30-3 6037
7 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
8 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
9 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
10 Vitamins Phase 4
11 Antiprotozoal Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
12 Folic Acid Antagonists Phase 4,Phase 1,Phase 2,Not Applicable
13 Antiparasitic Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
14 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
15 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 3,Phase 1
16 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 2,Phase 3,Phase 1
17 Antitubercular Agents Phase 4,Phase 2,Phase 3,Phase 1
18 Vitamin B9 Phase 4,Phase 1,Phase 2,Not Applicable
19 Folate Phase 4,Phase 1,Phase 2,Not Applicable
20 Antimalarials Phase 4,Phase 1,Phase 2
21 Vitamin B Complex Phase 4,Phase 1,Phase 2,Not Applicable
22 Lipid Regulating Agents Phase 4,Phase 1
23 Hypolipidemic Agents Phase 4,Phase 1
24 Antimetabolites Phase 4,Phase 1,Not Applicable
25 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
26 Vaccines Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
27
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
28
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3,Not Applicable 302-25-0
29
Prednisolone Approved, Vet_approved Phase 2, Phase 3,Not Applicable 50-24-8 5755
30
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3,Not Applicable 2921-57-5
31
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 3 22916-47-8 4189
32
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3,Not Applicable 83-43-2 6741
33
Aluminum sulfate Approved Phase 2, Phase 3,Phase 3 10043-01-3
34
Leuprolide Approved, Investigational Phase 3 53714-56-0 657181 3911
35
Goserelin Approved Phase 3 65807-02-5 5311128 47725
36
Miltefosine Approved, Investigational Phase 3 58066-85-6 3600
37
Benzoyl peroxide Approved Phase 3 94-36-0 7187
38
Clindamycin Approved, Vet_approved Phase 3 18323-44-9 29029
39
Streptomycin Approved, Vet_approved Phase 2, Phase 3,Phase 1 57-92-1 19649
40
Perphenazine Approved Phase 3 58-39-9 4748
41
Amitriptyline Approved Phase 3 50-48-6 2160
42
Tramadol Approved, Investigational Phase 3 27203-92-5 33741
43
Infliximab Approved Phase 3 170277-31-3
44
Clarithromycin Approved Phase 2, Phase 3 81103-11-9 84029
45
Prednisolone hemisuccinate Experimental Phase 2, Phase 3,Not Applicable 2920-86-7
46
meglumine antimoniate Experimental, Investigational Phase 3,Early Phase 1 133-51-7
47 Hormones Phase 2, Phase 3,Phase 3,Not Applicable
48 Hormone Antagonists Phase 2, Phase 3,Not Applicable
49 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3,Not Applicable
50 Peripheral Nervous System Agents Phase 2, Phase 3,Phase 3,Not Applicable

Interventional clinical trials:

(show top 50) (show all 58)
# Name Status NCT ID Phase Drugs
1 Effect of Additional Clofazimine on Erythema Nodosum Leprosum (ENL) Reactions in Leprosy Completed NCT01290744 Phase 4 Clofazimine;Placebo
2 Uniform Multidrug Therapy Regimen for Leprosy Patients Completed NCT00669643 Phase 4 PB 6 doses - Rifampicin and Dapsone;PB 6 doses - Rifampicin, Clofazimine and Dapsone;MB 12 doses - Rifampicin, Clofazimine and Dapsone;MB 6 doses - Rifampicin, Clofazimine and Dapsone
3 Effect of Weight and/or Obesity on Dapsone Drug Concentrations Completed NCT01165840 Phase 4 Dapsone
4 Feasibility and Effectiveness of Community Based Isoniazid Preventive Therapy in Kenya Completed NCT00850915 Phase 4
5 Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome Recruiting NCT02550080 Phase 4 Dapsone
6 Clinical Study on Combined Immune Effect of EV71 Inactivated Vaccine Recruiting NCT03519568 Phase 4
7 Minocycline Therapy for Lung Scarring in Patients With Idiopathic Pulmonary Fibrosis - a Pilot Study Unknown status NCT00203697 Phase 3 minocycline
8 Ciclosporin in the Management of New Type 1 Reactions in Leprosy Completed NCT00919815 Phase 2, Phase 3 Ciclosporin;Prednisolone
9 Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With Positive Response to Leishmanin (LST>0) Completed NCT00429780 Phase 2, Phase 3
10 Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With no Response to Leishmanin Completed NCT00429715 Phase 2, Phase 3
11 Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary Tuberculosis(Category I) Patients. Completed NCT00341328 Phase 3
12 Efficacy and Safety Study of Immunomodulator as an Adjunct Therapy in Pulmonary Tuberculosis (TB) Retreatment Patients Completed NCT00265226 Phase 3
13 Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer Completed NCT00004635 Phase 3 Thalidomide;leuprolide acetate;goserelin
14 Efficacy Trial on Oral Miltefosine in Comparison With Glucantime in the Treatment of ACL Caused by L. Tropica Completed NCT00351520 Phase 3 Miltefose
15 To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC® Gel Completed NCT02005666 Phase 3 Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel;DUAC® Gel;Placebo
16 Treatment of Neuropathic Pain in Leprosy Recruiting NCT03324035 Phase 3 Amitriptyline;Placebo oral capsule;Tramadol
17 Thalidomide Versus Infliximab in New Onset Crohn's Disease With Poor Prognostic Factors Recruiting NCT03221166 Phase 3 Thalidomide;Infliximab
18 WHO Drug Study for Buruli Ulcer - Comparison of SR8 and CR8 Active, not recruiting NCT01659437 Phase 2, Phase 3 Clarithromycin Extended Release;Streptomycin intramuscular injection
19 Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar Not yet recruiting NCT03662022 Phase 3 Rifampicin
20 Leprosy Skin Test Antigens Trial Completed NCT00128193 Phase 2
21 Ciclosporin in the Management of Steroid Resistant Type 1 Reactions in Leprosy Completed NCT00919451 Phase 2 ciclosporin
22 Ciclosporin in the Management of Chronic or Recurrent Erythema Nodosum Leprosum Completed NCT00919776 Phase 2 prednisolone;ciclosporin
23 Ciclosporin in the Management of New Erythema Nodosum Leprosum Completed NCT00919542 Phase 2 Ciclosporin;prednisolone
24 Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas Completed NCT00047879 Phase 2 Thalidomide
25 Progression of HIV-Disease Under Low Dose Corticosteroids Completed NCT01299948 Phase 2 Prednisolone
26 A Study to Evaluate the Efficacy and Safety of Bedaquiline (TMC207) in Participants With Multibacillary Leprosy Recruiting NCT03384641 Phase 2 Bedaquiline 200 mg
27 CC-11050 Trial in Nepalese Patients With Erythema Nodosum Leprosum Recruiting NCT03807362 Phase 2 CC-11050
28 Efficacy and Safety of Low Dose Thalidomide in Thalassemia Intermedia Recruiting NCT03651102 Phase 2 Thalidomide Oral Product
29 Virgin Coconut Oil Oral Supplementation for Leprosy Patients Withdrawn NCT01885611 Phase 1, Phase 2
30 Prevention of Disability: Proposal for a Guidance Manual for Leprosy Patients Completed NCT01006759 Phase 1
31 Leprosy Skin Test Antigens Phase 1 Completed NCT01920750 Phase 1
32 Study of the Safety and Immunogenicity of Bacille Calmette Guerin (BCG) Vaccine Completed NCT00654316 Phase 1
33 Measurement of Anti-TB Drugs in Lung Tissue From Patients Having Surgery to Treat Tuberculosis Completed NCT00816426 Phase 1 Rifampicin;Isoniazid;Pyrazinamide;Kanamycin;Moxifloxacin
34 Phase 1 LEP-F1 + GLA-SE Vaccine Trial in Healthy Adult Volunteers Active, not recruiting NCT03302897 Phase 1
35 Low Level Laser Therapy Effects in Peripheral Nerves Patient With Leprosy. Unknown status NCT03072004 Not Applicable
36 Montelukast in ENL Reaction Unknown status NCT00406861 Not Applicable montelukast in treatment of ENL reaction
37 Microcirculatory Impairment in Patients With Leprosy Completed NCT02085317 Not Applicable acetylcholine Iontophoresis;sodium nitroprusside Iontophoresis
38 Molecular Epidemiology of Leprosy - Philippines Completed NCT00315809
39 The Use of Low Level Laser Therapy for Wound Healing in Leprosy Patients Completed NCT00860717 Not Applicable
40 Molecular and Immunological Tools for Detection of Strain Diversity, Drug Resistance and Immunological Responses Completed NCT00138437
41 Impact of the Virtual Human Project on Team-based Learning: A Randomized-controlled Trial Completed NCT02484469 Not Applicable
42 SMF to Improve Performance of Microscopy for the Diagnosis of PTB in a High HIV Prevalence Setting Completed NCT02701439
43 CD8 Reactivity to Microorganisms in Blood and Breast Milk Completed NCT03084614
44 γ-irradiated BCG to Train Innate Immunity Completed NCT02259608 Not Applicable
45 Granuloma Annulare Treated With Rifampin, Ofloxacin, and Minocycline Combination Therapy Completed NCT00720980
46 Platelet Rich Plasma and Perineural Injection Therapy for Carpal Tunnel Syndrome Completed NCT02696161 Not Applicable
47 Genetics of Hepatitis C Virus Infection Completed NCT00005657
48 Toll-like Receptor 2 Gene Polymorphism, Serum Cytokines and Susceptibility to Disease Severity or Treatment Response of Pulmonary Tuberculosis Completed NCT00772408
49 Efficacy of Topical Liposomal Form of Drugs in Cutaneous Leishmaniasis Completed NCT01050777 Early Phase 1 Liposomal meglumine antimoniate (Glucantime);Liposomal meglumine antimoniate;Liposomal Paromomycin;Placebo
50 Self-verification and Support Via Mobile Phones Drastically Improves Tuberculosis Treatment Success in LMIC Settings Completed NCT03135366 Not Applicable

Search NIH Clinical Center for Hansen's Disease

Inferred drug relations via UMLS 74 / NDF-RT 52 :
Sources

Genetic Tests for Hansen's Disease

About this section
Sources

Anatomical Context for Hansen's Disease

About this section

MalaCards organs/tissues related to Hansen's Disease:

42
Skin, Testes, Eye, T Cells, Bone, Prostate, Breast
Sources

Publications for Hansen's Disease

About this section

Articles related to Hansen's Disease:

(show top 50) (show all 2292)
# Title Authors Year
1
Trichoscopic findings of eyebrow alopecia in patients with multibacillary leprosy. ( 30613952 )
2019
2
Lucio Phenomenon mimicking antiphospholipid syndrome: the occurrence of antiphospholipid antibodies in a leprosy patient. ( 30666664 )
2019
3
Molecular epidemiology of locally acquired Hansen's disease in Central Florida. ( 30654071 )
2019
4
Orthotic treatment for refractory plantar ulcers using distribution assessments of sensory disturbance and dynamic plantar pressure in patients with Hansen's disease: A case series. ( 30714641 )
2019
5
Hansen's disease deformities in a high risk area in Mozambique: A case study. ( 30726314 )
2019
6
Physical disability and Hansen's disease in Brazil in the 21st century: Brief analysis. ( 30726477 )
2019
7
Mycobacterium lepromatosis Lepromatous Leprosy in US Citizen Who Traveled to Disease-Endemic Areas. ( 30666944 )
2019
8
Does histoid leprosy represent a locally hyperimmune variant of lepromatous leprosy? ( 30778548 )
2019
9
Lepromatous leprosy masquerading as anetoderma in a boy. ( 30829294 )
2019
10
Borderline lepromatous leprosy masking as tinea versicolor. ( 30891732 )
2019
11
Increased CD5+ B-cells are associated with autoimmune phenomena in lepromatous leprosy patients. ( 30904499 )
2019
12
Visibly enlarged peripheral nerves in lepromatous leprosy. ( 30910939 )
2019
13
Neurosurgical treatment of leprosy neuropathy in a low-incidence, European country. ( 30903414 )
2019
14
Verrucous carcinoma on the foot arising in a chronic neuropathic ulcer of leprosy. ( 30841011 )
2019
15
Unusual association of leprosy with Lucio phenomenon with secondary antiphospholipid antibody syndrome and ischemic stroke. ( 30688250 )
2019
16
Comment on "Ichthyosiform sarcoidosis: a mimic of leprosy?" ( 30822369 )
2019
17
Reply to comment on "Ichthyosiform sarcoidosis: a mimic of leprosy?" ( 30903704 )
2019
18
Alternate Anti-Leprosy Regimen for Multidrug Therapy Refractory Leprosy: A Retrospective Study from a Tertiary Care Center in North India. ( 30298809 )
2019
19
Leprosy services in primary health care in India: comparative economic cost analysis of two public-health settings. ( 30444947 )
2019
20
Wide Awake Tendon Transfers in Leprosy Patients in India. ( 30470333 )
2019
21
Detection of Mycobacterium lepromatosis in patients with leprosy in India [Retraction]. ( 30613155 )
2019
22
Performance of serological tests PGL1 and NDO-LID in the diagnosis of leprosy in a reference Center in Brazil. ( 30616580 )
2019
23
Leprosy survey among rural communities and wild armadillos from Amazonas state, Northern Brazil. ( 30629624 )
2019
24
Notch signaling induces lymphoproliferation, T helper cell activation and Th1/Th2 differentiation in leprosy. ( 30629982 )
2019
25
Community knowledge, attitude, and perceived stigma of leprosy amongst community members living in Dhanusha and Parsa districts of Southern Central Nepal. ( 30633780 )
2019
26
Transcription factors STAT-4, STAT-6 and CREB regulate Th1/Th2 response in leprosy patients: effect of M. leprae antigens. ( 30642265 )
2019
27
Involvement of TNF-Producing CD8+ Effector Memory T Cells with Immunopathogenesis of Erythema Nodosum Leprosum in Leprosy Patients. ( 30652669 )
2019
28
Survival of Mycobacterium leprae and association with Acanthamoeba from environmental samples in the inhabitant areas of active leprosy cases: A cross sectional study from endemic pockets of Purulia, West Bengal. ( 30658215 )
2019
29
Analysis of the rs2476601 polymorphism of PTPN22 in Mexican mestizo patients with leprosy. ( 30675352 )
2019
30
'Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009-2015' - Author's reply. ( 30682406 )
2019
31
Differential immunoglobulin and complement levels in leprosy prior to development of reversal reaction and erythema nodosum leprosum. ( 30689631 )
2019
32
Assessing the Impact of the Twin Track Socio-Economic Intervention on Reducing Leprosy-Related Stigma in Cirebon District, Indonesia. ( 30691157 )
2019
33
Picturing health: a new face for leprosy. ( 30691701 )
2019
34
The mystery of 'saturation gap': a case of dapsone-induced methaemoglobinemia in a pregnant mother with leprosy. ( 30697428 )
2019
35
When amplified Mycobacterium tuberculosis direct (MTD) testing confuses leprosy diagnosis: A case report. ( 30705932 )
2019
36
Chronic aspects of leprosy-neglected but important. ( 30715525 )
2019
37
Abandoning the stigma of leprosy. ( 30722951 )
2019
38
"If you will counsel properly with love, they will listen": A qualitative analysis of leprosy affected patients' educational needs and caregiver perceptions in Nepal. ( 30726259 )
2019
39
Spatial approach of leprosy in the State of São Paulo, 2009-2012. ( 30726461 )
2019
40
Erythroderma as a manifestation of leprosy. ( 30726471 )
2019
41
Plantar ulcer occurrence among leprosy patients in Northern Nigeria: A study of contributing factors. ( 30729926 )
2019
42
Brain and Spinal Cord Lesions in Leprosy: A Magnetic Resonance Imaging-Based Study. ( 30761984 )
2019
43
Correspondence to histoid leprosy: a retrospective clinicopathological study from central Nepal. ( 30773622 )
2019
44
British Red Squirrels Remain the Only Known Wild Rodent Host for Leprosy Bacilli. ( 30775369 )
2019
45
De novo histoid leprosy in a Colombian patient with multiple skin nodules on the ears and extremities. ( 30785530 )
2019
46
Risk factors for physical disability upon release from multidrug therapy in new cases of leprosy at a referral center in Brazil. ( 30785567 )
2019
47
A 10-year Retrospective Descriptive Study on Pure Neuritic Leprosy from a Tertiary Referral Centre. ( 30788282 )
2019
48
Leprosy in a Midwestern Dermatology Clinic: Report of 9 Patients. ( 30799052 )
2019
49
Comment on "Bullous Erythema Nodosum Leprosum as the First Manifestation of Multibacillary Leprosy: A Rare Phenomenon". ( 30801346 )
2019
50
Umbilicated Lesions in a de novo case of histoid leprosy. ( 30821419 )
2019
Sources

Variations for Hansen's Disease

About this section
Sources

Expression for Hansen's Disease

About this section
Search GEO for disease gene expression data for Hansen's Disease.
Sources

Pathways for Hansen's Disease

About this section
Sources

GO Terms for Hansen's Disease

About this section
Sources

Sources for Hansen's Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....